In ex-vivo human gut models, TRI-01 induces its lead target species Agathobaculum butyriciproducens — a neuroprotective keystone species — by +45-fold, alongside increases in three further keystone species.

What's shown today

Ex-vivo induction of the target consortium

In ex-vivo human gut models (donor-stool fermentation), TRI-01 selectively increases its four target keystone species:

SpeciesFold-change (ex-vivo)
Agathobaculum butyriciproducens+45-fold standalone
Coprococcus catus+15-fold standalone
Anaerostipes hadrus+9-fold standalone
Faecalibacillus intestinalis+9-fold standalone
1× 3× 9× 15× 45× fold induction (log) the gut community → all four targets up Agathobaculum butyriciproducens — ×45 ×45 Coprococcus catus — ×15 ×15 Anaerostipes hadrus — ×9 ×9 Faecalibacillus intestinalis — ×9 ×9
  • Agathobaculum butyriciproducens×45
  • Coprococcus catus×15
  • Anaerostipes hadrus×9
  • Faecalibacillus intestinalis×9
Schematic — end-point values as measured Ex-vivo human gut models, donor-stool fermentation. Fold change for each of the four target species at end point, dosed on its own. The rest of the community is drawn at baseline to give the four some scale. We did not measure it.

Ex-vivo human gut models are the standard system for establishing that an ingredient shifts named species. This is the mechanistic foundation the human programme is built on.

Published science on the lead species

The target species are not arbitrary. Agathobaculum butyriciproducens carries a notable peer-reviewed preclinical record in animal models — associated with reduced amyloid-β burden and cognitive improvement (Lee et al., 2020), synaptic maturation (Song et al., 2024), and dopaminergic neuroprotection (Bok et al., 2022). This is peer-reviewed work on the species themselves, and it is why these four were chosen as targets.

What's planned

Our evidence deepens in a deliberate sequence: controlled human work on TRI-01 beginning with gut-health endpoints, and a parallel track for TRI-04 toward its metabolic-health claim path. Each stage is built to convert mechanism into substantiation a brand can put on pack.

Designs, endpoints and timing are shared with partners under confidentiality. A cognitive endpoint is the long-horizon goal for TRI-01.

A third-party signal

Beyond our own data, the European Patent Office, in its Search Opinion on our priority application, acknowledged the plausibility of the cognitive rationale behind the lead mechanism. The exact wording — with its hedges preserved — is on the IP page.

The claim ladder

Evidence and claims move together. At launch, the data supports gut-health structure-function claims. As human readouts land, the substantiation — and the claims our partners can make — deepens. We price and position to that ladder.

How it works Quality & manufacturing
What stage is the evidence at?
Ex-vivo induction of the four target species in human gut models, plus published peer-reviewed literature on the species. The human programme follows.
What can a brand claim today?
Gut-health structure-function claims at launch, with the ceiling rising as human readouts land.
What did the EPO say?
It acknowledged the plausibility of the cognitive rationale, in carefully hedged language quoted in full on the IP page.
What is an ex-vivo human gut model?
A fermentation system seeded with human donor stool, used to measure how a compound changes the microbial community. It is the standard way to test whether an ingredient shifts named species before a human trial.
At what dose was the effect measured?
In ex-vivo human gut models at the intake the product is designed for. Dose detail for each active sits on its own product page.